Effect of chronic kidney disease on adverse drug reactions to anti-tubercular treatment: a retrospective cohort study
Divya Datta Indu Ramachandra Rao Attur Ravindra Prabhu Shankar Prasad Nagaraju Girish Thunga Rahul Magazine Shivashankar Kaniyoor Nagri Raghavendra Shetty Nisha Abdul Khader Dharshan Rangaswamy Srinivas Vinayak Shenoy Mohan V. Bhojaraja Asha Kamath a Department of Nephrology,Kasturba Medical College,Manipal,Manipal Academy of Higher Education,Manipal,Karnataka,Indiab Department of Pharmacy Practice,Manipal College of Pharmaceutical Sciences,Manipal,Manipal Academy of Higher Education,Manipal,Karnataka,Indiac Department of Respiratory Medicine,Kasturba Medical College,Manipal,Manipal Academy of Higher Education,Manipal,Karnataka,Indiad Department of Medicine,Kasturba Medical College,Manipal,Manipal Academy of Higher Education,Manipal,Karnataka,Indiae Navitas Life Sciences Pvt. Ltd,Manipal,Karnataka,Indiaf Department of Data Science,Prasanna School of Public Health,Manipal,Manipal Academy of Higher Education,Manipal,Karnataka,India
DOI: https://doi.org/10.1080/0886022x.2024.2392883
IF: 3.222
2024-08-23
Renal Failure
Abstract:Introduction Patients with chronic kidney disease (CKD) are at increased risk of developing tuberculosis (TB). These patients may also be at higher risk of developing antitubercular treatment (ATT)-associated adverse drug reactions (ADRs). Although dose modification has been recommended, data regarding the impact of impaired kidney function on ATT-associated ADRs is sparse. We studied the incidence and profile of ATT-associated ADRs in patients with CKD and compared them with those with normal kidney function.
urology & nephrology